Skip to main content

Table 2 FDA approved Antibody-Drug Conjugates and selected others undergoing clinical development for cancer therapy

From: Targeted drug delivery for cancer therapy: the other side of antibodies

Generic name Trade/code name Target Antibody source Antibody isotype Other manipulations Conjugated to: Clinical status Indication
Gemtuzumab ozogamicin Mylotag® CD33 Mouse monoclonal IgG4- kappa Humanized Calicheamicin Approved 2000 WITHDRAWN 2010 CD33+AML
Brentuximab vedotin Adcentris™ CD30 (TNFR) Mouse monoclonal IgG1- kappa Chimeric Monomethyl auristatin E (MMAE) Approved 2011 HL
Trastuzumab emtansine MCC-DM1/ T-DM1 HER-2 Mouse monoclonal IgG1- kappa Humanized Maytansinoid DM1 Phase III HER-2+ MBC
Inotuzumab ozogamicin CMC-544 CD22 Mouse monoclonal IgG4- kappa Humanized Calicheamicin Phase III Phase II NHL DLBCL
Lorvotuzumab mertansine IMGN901 CD56 Mouse monoclonal IgG1- kappa Humanized Maytansinoid DM1 Orphan Drug 2010; Phase II SMLC, OC, MM
------ SAR3419 CD19 Mouse monoclonal IgG1 Humanized Maytasinoid DM4 Phase I NHL
  1. Legend: AML – Acute myologenous leukemia; HL – Hodgkin’s lymphoma; NHL – Non Hodglin’s Lymphoma, MM – Multiple Myeloma; DLBLC – Diffuse large B cell lymphoma; OC – Ovarian cancer; MBC – Metastatic breast cancer.